( January 22, 2025, 1:53 PM EST) -- KANSAS CITY, Kan. — Mylan NV, Mylan Specialty LP and Mylan Pharmaceuticals Inc. (collectively, Mylan) have agreed to contribute $73 million to a settlement fund to end claims that they conspired with others in an attempt to delay entry of generic competitors for the EpiPen XE "EpiPen" epinephrine autoinjector (EAI) into the market, according to a motion for preliminary approval of a class action settlement agreement filed by a pharmacy and other plaintiffs....